Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Male sex~  * 18 - 50 years of age~ * Hypogonadism following observational period of a minimum of 12 weeks since AAS discontinuation OR hypogonadism with a urine sample negative for AAS analyses at screening visit: plasma total testosterone ≤ 10 nmol/L AND featuring at least one symptom of male hypogonadism using IIEF in terms of erectile function (IIEF: Q1 - Q5 + Q15; total score \< 26) and/or sexual desire (IIEF: Q11 + Q12; total \< 7) (1) and/or ADAM questionnaire (YES to three questions other than question 1 and 7) and/or regular use of medical treatment for erectile dysfunction.~ * Motivation for permanent AAS cessation~Exclusion Criteria:~* Established cardiovascular disease~  * Established diabetes of any kind 384~ * Congenital hypogonadal conditions (cryptorchidism, Klinefelter's disease, Kallmann's disease etc.)~ * Previous established hypogonadal conditions due to other causes than illicit use of AAS~ * Current or previous treatment with testosterone on other indication than AAS-induced male hypogonadism~ * Abnormal puberty development (small testes, late or absent pubic hairing, late or absent deepening of voice, etc.)~ * Current or previous pituitary diseases including pituitary tumors~ * Current or previous tumors of the hypothalamus~ * Current or former testicular cancer~ * Current or previous prostate cancer~ * Current or previous breast cancer~ * Other cancers unless complete remission ≥ 5 year~ * Other concomitant disease or makes the patient unsuitable to participate in the study~ * Severely impaired liver function~ * Allergy or hypersensitivity to the active substance (letrozole) or excipients of Letrozol Accord® listed in Appendix D~ * Allergy or hypersensitivity to the active substance (hCG) or excipients of Brevactid® listed in Appendix D~ * Established Lapp lactase deficiency or glucose/galactose malabsorption~ * Severe venous phlebitis or current or previous venous thromboembolism~ * Inguinal hernia~ * treatment which according to the investigators' assessment~ * Simultaneous participation in another clinical study~ * Unable to follow treatment instructions in terms of study medication instructions~ * Ongoing criminal behavior in terms of violence or illicit distribution of drugs~ * Currently or in the foreseeable future included in anti-doping programs

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Active Comparator - placebo (Type: PLACEBO_COMPARATOR): Intervention: Intramuscular injection - placebo Intervention: Drug: placebo
- Active comparator - treatment (Type: ACTIVE_COMPARATOR): Intervention: intramuscular injection - hCG Intervention: Drug: Letrozole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues